Immunotherapeutic Potential of RNA-Modifying Drugs and MicroRNAs in Acute Myeloid Leukemia
Researchers reviewed epitranscriptomics and the prospects of precision medicines that target AML-associated genes.
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
Therapeutic Drug Monitoring Improved Incidence of Pleural Effusion With Dasatinib for CP-CML
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Treatment Strategies and Challenges in Chronic Lymphocytic Leukemia
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
HDMTX Promising for Patients With Primary CNS Lymphoma Ineligible for Clinical Trials
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
Venetoclax Plus Obinutuzumab Prolongs PFS, Not OS, in Chronic Lymphocytic Leukemia
At 4 years, there was no significant difference in overall survival.
Acalabrutinib Seems Safe and Efficacious in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Safe, Successful, Even Outside Clinical Trials
A retrospective study demonstrates that TKI therapy discontinuation occurs frequently and successfully both in clinical trials and in the general population.
JAK/STAT Inhibition May Be Promising in AF10-Rearranged Leukemia
Researchers sought to determine whether JAK1 inhibition would be a therapeutic target in patients with AF10-rearranged acute myeloid leukemia.
Gemtuzumab Ozogamicin Can Improve Outcomes in Pediatric KMT2A-Rearranged Acute Myeloid Leukemia
Gemtuzumab ozogamicin improved event-free survival and disease-free survival.
Phase 3 Trial Evaluates Inotuzumab Ozogamicin Plus Frontline Chemotherapy in B-Cell ALL
Investigators seek to evaluate how the addition of inotuzumab ozogamicin to frontline chemotherapy affects patients with newly diagnosed B-cell ALL.
CAR T Cell Therapy May Not Improve Survival vs Chemotherapy in B-ALL After Allo-HSCT
Researchers sought to determine whether CAR T therapy would have a better result than pretransplant chemotherapy in patients with B-ALL undergoing allo-HSCT.
Reducing Maintenance Produced ‘Outstanding’ Survival Outcomes in Pediatric Acute Lymphoblastic Leukemia
Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.
Transcranial Direct Current Stimulation in Adult Survivors of Pediatric Acute Lymphoblastic Leukemia
The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.
Gene Mutations in IDH-Mutated Acute Myeloid Leukemia Have Prognostic Significance
Researchers sought to determine what genetic mutations may have prognostic significance for chemotherapy and stem cell transplant in patients with AML.
Integrated Palliative Care Improves Symptoms, Coping in Patients Hospitalized for Acute Myeloid Leukemia Treatment
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Umbralisib Shows Promise Among Patients With CLL Intolerant to BTK, PI3K Inhibitors
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
Leukemia-Specific T-cells Promising for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Researchers sought to determine whether leukemia-specific T-cells would be a safe treatment for patients with AML or MDS after HSCT.
CLL/SLL: Ibrutinib, Venetoclax Therapy May Improve Outcomes in First Line
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
Tisagenlecleucel Appears Effective in Babies With Advanced B-Cell Acute Lymphoblastic Leukemia
The 12-month overall survival rate was 88%.
Relapsed/Refractory, IDH2-Mutated AML: Olutasidenib Shows Promise
IDH1 differentiation syndrome of any grade was noted in 14% of patients, with 1 fatal case.
CML: COVID-19 May Be Fatal in More Than 5% of Patients
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
At-Home Chemotherapy Appears Safe, Feasible for Acute Myeloid Leukemia, Myelodysplastic Syndromes
Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.
MEK Inhibitors May Overcome Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
New Prognostic Model for Patients With Acute Myeloid Leukemia With High-Risk Mutations
Researchers sought to identify a new model for predicting survival in patients with with acute myeloid leukemia.
Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
Phase 4 Feasibility Trial Is Evaluating At-Home Treatment of MRD-Positive BCP-ALL
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
High CMR Rates With Ponatinib Plus Blinatumomab in Adult Ph+ ALL
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
Chronic Myeloid Leukemia: What Your Patients Need to Know
Chronic myeloid leukemia (CML) can be painful and life-threatening if it is not caught in time. How can you educate patients with symptoms or who are newly diagnosed about the detection, symptoms, risk factors, and treatment of CML?
Epigenetic Mutations Affect Acute Myeloid Leukemia Outcomes in Elderly Patients
Researchers sought to determine whether epigenetic mutations may affect AML outcomes in elderly patients, and how that can inform use of decitabine-based regimens.
Acute Lymphoblastic Leukemia Patients With Half-Matched Donors See Improved Outcomes
Outcomes have improved during the past decade for patients with acute lymphoblastic leukemia who undergo haploidentical hematopoietic cell transplantation.
Calorie Restriction May Increase Efficacy of Chemotherapy in Younger Patients With B-ALL
The IDEAL trial found that adolescents and young adults with B-cell acute lymphoblastic leukemia may benefit from restrictive diets and increased exercise.
Chimeric Antigen Receptor T-Cell Therapy Shows Positive Results in Pediatric Patients With B-Cell ALL
Researchers sought to determine the long-term safety and efficacy of KTE-X19 in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Azacitidine Shows Safety in Infants With KMT2A-Mutant Acute Lymphoblastic Leukemia
Researchers sought to determine whether using azacitidine would be safe for infants with ALL with a KMT2A rearrangement.
Children With Down Syndrome at Higher Risk for Leukemia
Risk particularly high for acute myeloid leukemia before age 5 years.
Characteristics of Immunoglobulin Supplementation in B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine what characteristics may drive physician decisions to give immunoglobulin supplementation for patients with B-cell ALL.
Combination Platelet and Blast Counts Predicts Outcomes in Pediatric Acute Lymphoblastic Leukemia
Researchers sought to determine whether combination platelet and blast counts would be a helpful predictive model for pediatric patients with ALL.
NR3C1 Mutations May Drive Glucocorticoid Resistance in Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine whether NR3C1 mutations might influence glucocorticoid resistance and treatment outcomes in pediatric patients with ALL.
Quizartinib Combination Therapies Effective in Frontline and First-Salvage Therapy in AML
Researchers sought to determine whether quizartinib-based combination therapies would be safe and effective treatment options for patients with AML.
Short-Term 6-TG Exposure During Treatment for Pediatric ALL Associated With Hepatic SOS
Investigators analyzed the association between hepatic SOS and short-term application of 6-TG in 3983 pediatric ALL patients.
Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Diet, Exercise Intervention Explored in Children With B-ALL
Reduction in fat gain not seen in overall cohort, but stratified analysis showed benefit among those overweight, obese at baseline.
Whole-Genome Sequencing Shows Promise for Risk Stratification in AML, MDS
Researchers sought to determine whether whole-genome sequencing may be a better risk stratification tool compared with conventional cytogenetic analysis.
Low-Dose Anthracycline in Induction Shows Better Safety in Patients With Acute Promyelocytic Leukemia
Researchers sought to determine whether a lower dose of anthracycline would have the same efficacy and better safety as standard dosage in patients with APL.
Certain Mutations May Be Associated With Infection Risk for Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Posttraumatic Stress Disorder Symptoms Seen in Patients With Acute Myeloid Leukemia
Researchers investigated whether there may be a trend of patients with AML developing symptoms of PTSD.
High Cortactin, HS1 Levels Predict Worse Survival in Patients With B Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether high cortactin and HS1 expression may be linked with poorer prognosis for patients with B-ALL.
Anti-CD20 Antibody Improved Response to Ibrutinib in High-Risk R/R CLL
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.
BTK Inhibitors for CLL Lower Response to Some Vaccines
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
Pre-Transplantation MRD Status Predicts Survival in Acute Leukemia
Researchers sought to determine whether MRD status could be a helpful prognostic tool for survival in patients with acute leukemia prior to allo-HSCT.
Case Study Shows Potential Protective Effect of TKI Therapy for Chronic Myeloid Leukemia
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Acute Kidney Injury Seen With Induction Chemotherapy for Acute Myeloid Leukemia
Researchers sought to determine the incidence and risk factors for acute kidney in patients with AML who are undergoing induction chemotherapy.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...